Company Overview

Corporate Profile

Ainos, Inc. (NASDAQ: AIMD) is a dual-platform AI and biotech company pioneering SmellTech, AI diagnostics, and immune therapeutics.

Ainos’ proprietary AI Nose platform uses a breakthrough smell language model (SLM) to digitize scent into Smell IDs, turning invisible chemical signals into machine-readable data. From robotics and smart factories to senior care and women’s health, Ainos is giving AI the power to smell, unlocking a new frontier in sensory intelligence. With strategic partners, Ainos is scaling the first commercial digital olfaction platform.

Ainos also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases, plus applications in animal health. Multiple clinical programs are in motion Active clinical programs include HIV-related oral warts, primary Sjögren’s syndrome, and feline chronic gingivostomatitis (FCGS).

The name “Ainos” fuses “AI” and “Nose”—our mission: digitize smell, empower machines, and transform industries. Pronounced “iNose,” we’re building AI’s missing sense.